Brief: Ascentage Pharma Group International Says Phase III Study Of Olverembatinib Cleared By FDA, EMA
05/12/2025 01:35
Dec 5 (Reuters) - Ascentage Pharma Group International 6855.HK: GLOBAL REGISTRATIONAL PHASE III STUDY OF OLVEREMBATINIB CLEARED BY FDA AND EMA Further company coverage: 6855.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group International Posts FY Loss Increased To RMB1,243 Million
Ascentage rises on progress of olverembatinib for blood cancer treatment
Brief: Ascentage Pharma Group International Says Phase III Study Of Olverembatinib Cleared By FDA, EMA
Brief: Ascentage Pharma Group International Posts HY Net Loss Was RMB590.8 Million
Brief: Ascentage Pharma Group International FDA And EMA Clear Phase Iii Study Of Lisaftoclax For Hr-Mds